Stay updated with breaking news from Repligen Co. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Equities analysts expect Repligen Co. (NASDAQ:RGEN – Get Rating) to post sales of $183.55 million for the current quarter, according to Zacks. Six analysts have issued estimates for Repligen’s earnings. The lowest sales estimate is $171.50 million and the highest is $193.21 million. Repligen posted sales of $142.84 million during the same quarter last year, […]
Wall Street analysts expect Repligen Co. (NASDAQ:RGEN – Get Rating) to post earnings per share (EPS) of $0.72 for the current quarter, Zacks Investment Research reports. Six analysts have made estimates for Repligen’s earnings. The lowest EPS estimate is $0.66 and the highest is $0.76. Repligen reported earnings per share of $0.68 during the same […]
National Asset Management Inc. boosted its stake in Repligen Co. (NASDAQ:RGEN – Get Rating) by 16.0% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 1,865 shares of the biotechnology company’s stock after buying an additional 257 shares during the quarter. National Asset Management […]
Repligen Co. (NASDAQ:RGEN – Get Rating) has received an average rating of “Buy” from the nine analysts that are covering the company, Marketbeat reports. Two research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The average 1 year price objective among analysts that have […]
Wall Street brokerages expect that Repligen Co. (NASDAQ:RGEN – Get Rating) will post $183.55 million in sales for the current fiscal quarter, Zacks Investment Research reports. Six analysts have provided estimates for Repligen’s earnings, with the lowest sales estimate coming in at $171.50 million and the highest estimate coming in at $193.21 million. Repligen posted […]